Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5Unknown 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 3Other solid neoplasm 1Dermatologic 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Glioblastoma 2Refractory Solid Tumors 1Recurrence 1Melanoma 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Interventional × verubulin × Clear all
NCT01285414 2012-04-11

Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

Myrexis Inc.

Phase 2 Completed
5 enrolled
CNS

Brain Neoplasms, Glioblastoma

NCT00892931 2011-10-14

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

Myrexis Inc.

Phase 2 Completed
56 enrolled
CNS

Brain Neoplasms, Glioblastoma, Recurrence

NCT00609011 2010-08-23

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

Myrexis Inc.

Phase 1/2 Completed
22 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00393965 2008-02-13

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Myrexis Inc.

Phase 1 Completed
18 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT00394446 2008-02-13

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Myrexis Inc.

Phase 1 Completed
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡